MERONI, MARICA
MERONI, MARICA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
2023 M.P. Moore, X. Wang, H. Shi, M. Meroni, A. Cherubini, L. Ronzoni, E.J. Parks, J.A. Ibdah, R.S. Rector, L. Valenti, P. Dongiovanni, I. Tabas
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
2023 R.M. Pipitone, F. Malvestiti, G. Pennisi, O. Jamialahmadi, P. Dongiovanni, G. Bertolazzi, J. Pihlajamäki, H. Yki-Järvinen, U. Vespasiani-Gentilucci, F. Tavaglione, S. Maurotti, C. Bianco, G. Di Maria, M. Enea, A.L. Fracanzani, V. Kärjä, G. Lupo, V. Männistö, M. Meroni, R. Piciotti, S. Qadri, R. Zito, A. Craxì, V. Di Marco, C. Cammà, C. Tripodo, L. Valenti, S. Romeo, S. Petta, S. Grimaudo
Recent advances of drugs monitoring in oral fluid and comparison with blood
2023 S. Casati, M. Binda, P. Dongiovanni, M. Meroni, A. D'Amato, G. Roda, M. Orioli, M. DEL FABBRO, G.M. Tartaglia
Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis
2023 J. Kang, J. Postigo-Fernandez, K. Kim, C. Zhu, J. Yu, M. Meroni, B. Mayfield, A. Bartolomé, D.H. Dapito, A.W. Ferrante, P. Dongiovanni, L. Valenti, R.J. Creusot, U.B. Pajvani
Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation
2023 P. Dongiovanni, M. Meroni, S. Casati, R. Goldoni, D.V. Thomaz, N.S. Kehr, D. Galimberti, M. Del Fabbro, G.M. Tartaglia
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b
2022 S.J. Patel, N. Liu, S. Piaker, A. Gulko, M.L. Andrade, F.D. Heyward, T. Sermersheim, N. Edinger, H. Srinivasan, M.P. Emont, G.P. Westcott, J. Luther, R.T. Chung, S. Yan, M. Kumari, R. Thomas, Y. Deleye, A. Tchernof, P.J. White, G.A. Baselli, M. Meroni, D.F. De Jesus, R. Ahmad, R.N. Kulkarni, L. Valenti, L. Tsai, E.D. Rosen
Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
2022 A. Cespiati, M. Meroni, R. Lombardi, G. Oberti, P. Dongiovanni, A.L. Fracanzani
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease
2022 R. Lombardi, R. Piciotti, P. Dongiovanni, M. Meroni, S.R. Fargion, A.L. Fracanzani
The α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. DI PIERRO, P. Dongiovanni
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
2021 M. Longo, M. Meroni, E. Paolini, C. Macchi, P. Dongiovanni
The rs599839 a>g variant disentangles cardiovascular risk and hepatocellular carcinoma in nafld patients
2021 M. Meroni, M. Longo, E. Paolini, A. Alisi, L. Miele, E.R. De Caro, G. Pisano, M. Maggioni, G. Soardo, L.V. Valenti, A.L. Fracanzani, P. Dongiovanni
Genetics is of the essence to face NAFLD
2021 M. Meroni, M. Longo, G. Tria, P. Dongiovanni
$\upalpha$-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study [alpha-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study]
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni
Nutrition and genetics in NAFLD : The perfect binomium
2020 M. Meroni, M. Longo, A. Rustichelli, P. Dongiovanni
β-Klotho gene variation is associated with liver damage in children with NAFLD
2020 P. Dongiovanni, A. Crudele, N. Panera, I. Romito, M. Meroni, C. De Stefanis, A. Palma, D. Comparcola, A.L. Fracanzani, L. Miele, L. Valenti, V. Nobili, A. Alisi
Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
2020 M. Meroni, M. Longo, P. Dongiovanni
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
2020 P. Dongiovanni, M. Meroni, S. Petta, M. Longo, A. Alisi, G. Soardo, L. Valenti, L. Miele, S. Grimaudo, G. Pennisi, G. Antonio, D. Consonni, S. Fargion, A.L. Fracanzani